Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus Price Target from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given a consensus recommendation of “Buy” by the eight research firms that are covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $36.50.

Several research firms have recently issued reports on BCAX. HC Wainwright raised their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research note on Wednesday, February 12th.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX opened at $13.35 on Tuesday. Bicara Therapeutics has a 12-month low of $11.10 and a 12-month high of $28.09. The business has a fifty day moving average of $13.28.

Institutional Trading of Bicara Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vestal Point Capital LP raised its stake in shares of Bicara Therapeutics by 67.1% in the 4th quarter. Vestal Point Capital LP now owns 710,000 shares of the company’s stock valued at $12,368,000 after purchasing an additional 285,000 shares during the period. Wexford Capital LP acquired a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $348,000. Red Tree Management LLC acquired a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $55,230,000. Nuveen Asset Management LLC acquired a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $436,000. Finally, Orbimed Advisors LLC increased its position in shares of Bicara Therapeutics by 9.7% in the fourth quarter. Orbimed Advisors LLC now owns 298,301 shares of the company’s stock valued at $5,196,000 after acquiring an additional 26,391 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.